Description

PT-141 (Bremelanotide)

• PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist developed to acutely enhance sexual desire by acting centrally on melanocortin pathways.
• Investigational and approved-formulation uses target hypoactive sexual desire disorder (HSDD) in specific patient populations.

Key benefits

• Rapid-onset modulation of sexual desire and arousal via central melanocortin receptor activation.
• Administered as an on-demand treatment (pre‑activity) rather than a daily therapy, providing episodic benefit.
• Demonstrated efficacy in increasing sexual desire and reducing distress associated with low desire in clinical studies.

Primary uses

• Clinically approved in some regions for treatment of HSDD in premenopausal women (when indicated by local labeling).
• Investigational use in research into sexual dysfunction and central melanocortin biology.

Who it’s for

• Adults meeting diagnostic and prescribing criteria for HSDD under clinician evaluation and guidance.
• Not appropriate for unsupervised use, recreational application, or use in men/women outside approved indications without medical oversight.

Suggested use

• Typically administered by subcutaneous injection shortly before anticipated sexual activity per prescribing instructions; follow local product labeling for dose and timing.
• Use only under clinician direction; screen and monitor for contraindications and adverse effects.

Safety and storage

• Common adverse effects: nausea, flushing, injection‑site reactions, headache. Transient increases in blood pressure have been reported.
• Contraindications/precautions: cardiovascular disease or uncontrolled hypertension; assess blood pressure before and after use as directed. Avoid use with contraindicated medications per product labeling.
• Not recommended in pregnant or breastfeeding individuals unless advised by a clinician.
• Store unopened product per manufacturer instructions (typically refrigerated); follow in‑use handling and disposal guidance for needles/syringes.

Quick facts

• Mechanism: melanocortin receptor agonist acting centrally to increase sexual desire.
• Administration: on‑demand subcutaneous injection per approved dosing schedules.
• Regulatory status: approved for specific indications in some regions (follow local prescribing information); investigational in others.
• Use only under prescription and clinician supervision.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.